Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | IGF2R | P11717 | 4/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HK2 | P52789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394667 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL20291477 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL4363197 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL29425232 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL4363206 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL25361382 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL14669223 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL20912983 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL20558753 | 1.00 | AMDHD2 (0.68) | AMDHD2FBP1MAPK1IGF2RLGALS3 | |
| SCHEMBL14414838 | 0.96 | AMDHD2 (0.62) | AMDHD2FBP1MAPK1IGF2RLGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-05-06 | — | — | US | disclosed |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | THE JOHN HOPKINS UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3558323-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | Etablissement Français du Sang (FR) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019055597-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TSC | National Tuberous Sclerosis Association, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | National Tuberous Sclerosis Association, Inc. | 2019-03-14 | — | — | US | disclosed |
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2018-10-04 | — | — | US | disclosed |
| WO-2018115476-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | ETABLISSEMENT FRANÇAIS DU SANG (FR) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280418-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | AMDHD2 1655/4885FBP1 1833/4885MAPK1 2051/4885 |
| US-10668092-B2 | Compositions and methods for treatment of inflammatory disorders | TLR4, TLR3, TLR2 | AMDHD2 1655/4885FBP1 1833/4885MAPK1 2051/4885 |
| US-20210128594-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | TLR4, TLR3, TLR2 | AMDHD2 1655/4885FBP1 1833/4885MAPK1 2051/4885 |
| US-20190077874-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBEROUS SCLEROSIS | TLR4, TLR3, TLR2 | AMDHD2 708/4885FBP1 846/4885MAPK1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.